ArticleCureus2024
Immunological Enigma: A Case Report of COVID-19 Survival in a Patient With Human Immunodeficiency Virus, Hepatitis C Virus, and Tuberculosis Co-infection.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report aims to elucidate the unique clinical course of a 34-year-old male patient diagnosed with human immunodeficiency virus (HIV), chronic hepatitis C, and prior tuberculosis (TB) infections, who subsequently contracted COVID-19. Immunological assessments revealed profound immunosuppression, marked by decreased CD4+ T cells (0.037 x 10⁹/L), alongside mildly elevated IgG levels (16.701 g/L), reflecting both HIV-related immunodeficiency and non-adherence to antiretroviral therapy (ART). Concurrently, the patient tested positive for SARS-CoV-2. Imaging findings demonstrated overlapping characteristics of TB and COVID-19. Timely initiation of specific TB therapy, alongside supportive care and optimized antiretroviral and anti-TB regimens, was implemented. Despite the patient's immunocompromised state and complex medical history, he successfully recovered from COVID-19. Key factors contributing to survival included early TB diagnosis and treatment, comprehensive medical care, careful management of drug interactions, and a potentially effective individual immune response. Notably, no typical features of COVID-19 pneumonia were observed, suggesting that the dual infection may have influenced the clinical presentation. This case underscores the potential for positive outcomes in individuals with complex medical histories, including coexisting infections. Further research into the interplay of multiple infections in such patients is warranted to optimize clinical management strategies and enhance our understanding of COVID-19 within this distinctive population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.